Loading clinical trials...

Mental Health Consequences of COVID19 Infection in the French RMD Cohort | Clinical Trials | Clareo Health

TERMINATED

Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort

NCT04510467•University Hospital, Lille

Summary

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient case:
•Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease
•With confirmed COVID-19 infection (at least one month prior to study inclusion)
•Study information given to the patient
•Patient affiliated to social security
•Patient control:
•Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease.
•Not having had a confirmed COVID-19 infection
•Study information given to the patient
•Patient affiliated to social security

Exclusion Criteria

•Opposition to participation in the study by the patient and/or his legal representative
•Adult patient not able to understand the implications and rules of the study
•Protected adults under guardianship or curatorship

Locations (1)

Hop Claude Huriez Chu Lille

Lille, France

Key Dates

Start Date

January 20, 2021

Primary Completion Date

May 19, 2022

Completion Date

May 19, 2022

Last Updated

January 13, 2023

Enrollment

296

ACTUAL participants

Conditions

Covid19Systemic Autoimmune DiseaseInflammatory RheumatismAuto Inflammatory Diseases

IDENTIFICATION OF BIOMARKERS ASSOCIATED WITH THE SEVERITY AND RADIO-CLINICAL PROGRESSION OF KNEE OSTEOARTHRITIS

NCT06600958

Knee OsteoarthritisChronic Inflammatory Rheumatism

View study

RECRUITING

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Inclusion Criteria

Exclusion Criteria

IDENTIFICATION OF BIOMARKERS ASSOCIATED WITH THE SEVERITY AND RADIO-CLINICAL PROGRESSION OF KNEE OSTEOARTHRITIS

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19